{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:43:53Z","timestamp":1781084633835,"version":"3.54.1"},"reference-count":45,"publisher":"The Endocrine Society","issue":"1","funder":[{"name":"ALF grants from Uppsala University Hospital"},{"DOI":"10.13039\/100011338","name":"AstraZeneca Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1210\/jc.2018-00969","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T14:05:09Z","timestamp":1534514709000},"page":"193-201","source":"Crossref","is-referenced-by-count":30,"title":["Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-7763","authenticated-orcid":false,"given":"Per","family":"Lundkvist","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-9295","authenticated-orcid":false,"given":"Maria J","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5627-8904","authenticated-orcid":false,"given":"Prasad G","family":"Kamble","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-3372","authenticated-orcid":false,"given":"Petros","family":"Katsogiannos","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Esterline","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Johnsson","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-9481","authenticated-orcid":false,"given":"Jan W","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"issue":"9","key":"2019041121153784800_B1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2337\/diacare.17.9.961","article-title":"Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men","volume":"17","author":"Chan","year":"1994","journal-title":"Diabetes Care"},{"issue":"9922","key":"2019041121153784800_B2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"2019041121153784800_B3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-125-3-199608010-00011","article-title":"Non-insulin-dependent diabetes mellitus in minorities in the United States","volume":"125","author":"Carter","year":"1996","journal-title":"Ann Intern Med"},{"issue":"8","key":"2019041121153784800_B4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2337\/diacare.19.8.827","article-title":"Parental history of diabetes in a population-based study","volume":"19","author":"Klein","year":"1996","journal-title":"Diabetes Care"},{"issue":"4","key":"2019041121153784800_B5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"2019041121153784800_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"Alsahli","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"2019041121153784800_B7","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041121153784800_B8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJM197007162830301","article-title":"Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion","volume":"283","author":"M\u00fcller","year":"1970","journal-title":"N Engl J Med"},{"issue":"11","key":"2019041121153784800_B9","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/db10-1032","article-title":"Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy","volume":"59","author":"Rizza","year":"2010","journal-title":"Diabetes"},{"issue":"2","key":"2019041121153784800_B10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2019041121153784800_B11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"issue":"22","key":"2019041121153784800_B12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2019041121153784800_B13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2019041121153784800_B14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2019041121153784800_B15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcjd.2017.08.242","article-title":"Glucagon-like peptide-1 receptor agonists: a class update for treating type 2 diabetes","volume":"41","author":"Lovshin","year":"2017","journal-title":"Can J Diabetes"},{"issue":"3","key":"2019041121153784800_B16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2019041121153784800_B17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2019041121153784800_B18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/dom.12889","article-title":"Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes","volume":"19","author":"Nystr\u00f6m","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2019041121153784800_B19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"2019041121153784800_B20","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2019041121153784800_B21","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"2019041121153784800_B22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"2019041121153784800_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-016-0160-4","article-title":"The insulin:glucagon ratio and the choice of glucose-lowering drugs","volume":"7","author":"Kalra","year":"2016","journal-title":"Diabetes Ther"},{"issue":"12","key":"2019041121153784800_B24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/diab.20.12.834","article-title":"Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses","volume":"20","author":"Unger","year":"1971","journal-title":"Diabetes"},{"issue":"8","key":"2019041121153784800_B25","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041121153784800_B26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"2019041121153784800_B27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/03009734.2016.1154905","article-title":"Glucose control of glucagon secretion-\u2018There\u2019s a brand-new gimmick every year\u2019","volume":"121","author":"Gylfe","year":"2016","journal-title":"Ups J Med Sci"},{"issue":"1","key":"2019041121153784800_B28","doi-asserted-by":"crossref","first-page":"31214","DOI":"10.1038\/srep31214","article-title":"Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells","volume":"6","author":"Pedersen","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"2019041121153784800_B29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s004240050558","article-title":"Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1","volume":"435","author":"Gromada","year":"1998","journal-title":"Pflugers Arch"},{"issue":"2","key":"2019041121153784800_B30","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"2019041121153784800_B31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diacare.19.6.580","article-title":"Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients","volume":"19","author":"Creutzfeldt","year":"1996","journal-title":"Diabetes Care"},{"issue":"1","key":"2019041121153784800_B32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13300-010-0013-5","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications","volume":"2","author":"Unger","year":"2011","journal-title":"Diabetes Ther"},{"issue":"11","key":"2019041121153784800_B33","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"issue":"8","key":"2019041121153784800_B34","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1210\/jc.2012-2396","article-title":"Mechanism of action of DPP-4 inhibitors--new insights","volume":"97","author":"Vella","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041121153784800_B35","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"10","key":"2019041121153784800_B36","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1210\/jc.2015-2725","article-title":"The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA trial","volume":"100","author":"Kramer","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041121153784800_B37","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2017-00928","article-title":"Impact of the glucagon assay when assessing the effect of chronic liraglutide therapy on glucagon secretion","volume":"102","author":"Kramer","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2019041121153784800_B38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4158\/EP14489.OR","article-title":"Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy","volume":"20","author":"Hansen","year":"2014","journal-title":"Endocr Pract"},{"issue":"6","key":"2019041121153784800_B39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.108.026088","article-title":"Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections","volume":"37","author":"Fura","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"2019041121153784800_B40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.clinthera.2013.06.017","article-title":"Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects","volume":"35","author":"Yang","year":"2013","journal-title":"Clin Ther"},{"key":"2019041121153784800_B41","unstructured":"Sach-Friedl S, Augustin T, Magnes C, Ekardt E, Eberl A, Narath S, Brunner M, Korsatko S, Evehlikova E, Treiber G, Pieber TR. Effect of dapagliflozin, saxagliptin, and the combination of the both on glucagon, endogenous glucose production (EGP) and glycerol in patients with type 2 diabetes. In: Proceedings of the European Association for the Study of Diabetes; 14 September 2017; Lisbon, Portugal. eAbstract 890."},{"key":"2019041121153784800_B42","doi-asserted-by":"crossref","unstructured":"Lee\n              M\n            , KimM, ParkJS, LeeS, YouJ, AhnCW, KimKR, KangS. Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients [published online ahead of print 8 September 2017]. Korean J Intern Med (Korean Assoc Intern Med). e-pub ahead of print. 10.3904\/kjim.2016.233","DOI":"10.3904\/kjim.2016.233"},{"issue":"5","key":"2019041121153784800_B43","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"2019041121153784800_B44","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"2019041121153784800_B45","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/1\/193\/27059822\/jc.2018-00969.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T04:39:23Z","timestamp":1555043963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/1\/193\/5075166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,8,17]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-00969","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,8,17]]}}}